Advertisement

Topics

Dermira Takes Roche's Lebrikizumab With Best-In-Class Ambitions

11:55 EDT 8 Aug 2017 | SCRIP

Dermira will focus on developing the IL-13 inhibitor in atopic dermatitis, where it sees an opportunity for potential dosing and...

      

Related Stories

 

Original Article: Dermira Takes Roche's Lebrikizumab With Best-In-Class Ambitions

NEXT ARTICLE

More From BioPortfolio on "Dermira Takes Roche's Lebrikizumab With Best-In-Class Ambitions"

Quick Search
Advertisement
 

Relevant Topic

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...